Holbrook Ek Kohrt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Holbrook Ek Kohrt has a total of 168 co-authors. Here are the top co-authors by number of shared publications:
Cariad Chester
Stanford University
8 shared publicationsRoch Houot
Service d'Hématologie Clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France. Inserm U917, Université de Rennes 1, Rennes, France
5 shared publicationsAurelien Marabelle
Institute de Gustave Roussy Service, Paris, France
4 shared publicationsIdit Sagiv-Barfi
Department of Medicine, Stanford University, Stanford, California
4 shared publicationsRonald Levy
Department of Medicine, Division of Oncology, Stanford University, Stanford, California, USA. 2CHU Rennes, Service Hématologie Clinique, Rennes, France. 3INSERM, U917, Rennes, France. 4Centre de Recherche en Cancérologie de Lyon, UMR INSERM U1052, CNRS 5268, Centre Léon Bérard, Université de Lyon, Lyon, France. 5Department of Immunobiology, Yale Cancer Center, New Haven, Connecticut, USA. 6Department of Pathology and Committee on Immunology, University of Chicago, Chicago, Illinois, USA
3 shared publications- Atsushi Yonezawa
Kyoto University Hospital
2 shared publications
Latest Publications
- 18 October 2016
- Published by Springer Nature
- p. 143-168
The Future in Ovarian Cancer: Advances in Immunotherapies
- 18 October 2016
- Published by Springer Nature
- p. 143-168
The Future in Ovarian Cancer: Advances in Immunotherapies
- 31 May 2016
- Published by Springer Nature
- p. 79-108
NK Cell Responses in Immunotherapy: Novel Targets and Applications
- 31 May 2016
- Published by Springer Nature
- p. 79-108
NK Cell Responses in Immunotherapy: Novel Targets and Applications
- Open Access
- 15 March 2016
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 4 (1) , 15
Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials
The efficacy of PD-1/PD-L1 targeted therapies in addition to anti-CTLA-4 solidifies immunotherapy as a modality to add to the anticancer arsenal. Despite raising the bar of clinical efficacy, immunologically targeted agents raise new challenges to conventional drug development paradigms by highlighting the limited relevance of assessing standard pharmacokinetics (PK) and pharmacodynamics (PD). Specifically, systemic and intratumoral immune effects have not consistently correlated with standard relationships between systemic dose, toxicity, and efficacy for cytotoxic therapies. Hence, PK and PD paradigms remain inadequate to guide the selection of doses and schedules, both starting and recommended Phase 2 for immunotherapies. The promise of harnessing the immune response against cancer must also be considered in light of unique and potentially serious toxicities. Refining immune endpoints to better inform clinical trial design represents a high priority challenge. The Cancer Immunotherapy Trials Network investigators review the immunodynamic effects of specific classes of immunotherapeutic agents to focus immune assessment modalities and sites, both systemic and importantly intratumoral, which are critical to the success of the rapidly growing field of immuno-oncology.
- 15 March 2016
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 4 (1) , 15
Open AccessImmunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials
The efficacy of PD-1/PD-L1 targeted therapies in addition to anti-CTLA-4 solidifies immunotherapy as a modality to add to the anticancer arsenal. Despite raising the bar of clinical efficacy, immunologically targeted agents raise new challenges to conventional drug development paradigms by highlighting the limited relevance of assessing standard pharmacokinetics (PK) and pharmacodynamics (PD). Specifically, systemic and intratumoral immune effects have not consistently correlated with standard relationships between systemic dose, toxicity, and efficacy for cytotoxic therapies. Hence, PK and PD paradigms remain inadequate to guide the selection of doses and schedules, both starting and recommended Phase 2 for immunotherapies. The promise of harnessing the immune response against cancer must also be considered in light of unique and potentially serious toxicities. Refining immune endpoints to better inform clinical trial design represents a high priority challenge. The Cancer Immunotherapy Trials Network investigators review the immunodynamic effects of specific classes of immunotherapeutic agents to focus immune assessment modalities and sites, both systemic and importantly intratumoral, which are critical to the success of the rapidly growing field of immuno-oncology.
- 14 February 2016
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 22 (4) , 787-789
Scientific Significance of Clinically Insignificant FcγRIIIa-V158F Polymorphism
Kenkre and colleagues report the absence of correlation between FcγRIIIa-V158F polymorphism and rituximab response in follicular lymphoma patients, a result which is in contrast with prior studies. This discrepancy recalls that many other factors (from the host and from the tumor) may influence the efficacy of rituximab in vivo. Clin Cancer Res; 22(4); 787–9. ©2015 AACR. See related article by Kenkre et al., p. 821
- 14 February 2016
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 22 (4) , 787-789
Scientific Significance of Clinically Insignificant FcγRIIIa-V158F Polymorphism
Kenkre and colleagues report the absence of correlation between FcγRIIIa-V158F polymorphism and rituximab response in follicular lymphoma patients, a result which is in contrast with prior studies. This discrepancy recalls that many other factors (from the host and from the tumor) may influence the efficacy of rituximab in vivo. Clin Cancer Res; 22(4); 787–9. ©2015 AACR. See related article by Kenkre et al., p. 821
- Open Access
- 8 February 2016
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 126 (3) , 921-937
Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma
Melanoma prognosis is dictated by tumor-infiltrating lymphocytes, the migratory and functional behavior of which is guided by chemokine or cytokine gradients. Here, we retrospectively analyzed the expression patterns of 9 homing receptors (CCR/CXCR) in naive and memory CD4+ and CD8+ T lymphocytes in 57 patients with metastatic melanoma (MMel) with various sites of metastases to evaluate whether T cell CCR/CXCR expression correlates with intratumoral accumulation, metastatic progression, and/or overall survival (OS). Homing receptor expression on lymphocytes strongly correlated with MMel dissemination. Loss of CCR6 or CXCR3, but not cutaneous lymphocyte antigen (CLA), on circulating T cell subsets was associated with skin or lymph node metastases, loss of CXCR4, CXCR5, and CCR9 corresponded with lung involvement, and a rise in CCR10 or CD103 was associated with widespread dissemination. High frequencies of CD8+CCR9+ naive T cells correlated with prolonged OS, while neutralizing the CCR9/CCL25 axis in mice stimulated tumor progression. The expansion of CLA-expressing effector memory CD8+ T cells in response to a single administration of CTLA4 blockade predicted disease control at 3 months in 47 patients with MMel. Thus, specific CCR/CXCR expression patterns on circulating T lymphocytes may guide potential diagnostic and therapeutic approaches.
- 8 February 2016
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 126 (3) , 921-937
Open AccessChemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma
Melanoma prognosis is dictated by tumor-infiltrating lymphocytes, the migratory and functional behavior of which is guided by chemokine or cytokine gradients. Here, we retrospectively analyzed the expression patterns of 9 homing receptors (CCR/CXCR) in naive and memory CD4+ and CD8+ T lymphocytes in 57 patients with metastatic melanoma (MMel) with various sites of metastases to evaluate whether T cell CCR/CXCR expression correlates with intratumoral accumulation, metastatic progression, and/or overall survival (OS). Homing receptor expression on lymphocytes strongly correlated with MMel dissemination. Loss of CCR6 or CXCR3, but not cutaneous lymphocyte antigen (CLA), on circulating T cell subsets was associated with skin or lymph node metastases, loss of CXCR4, CXCR5, and CCR9 corresponded with lung involvement, and a rise in CCR10 or CD103 was associated with widespread dissemination. High frequencies of CD8+CCR9+ naive T cells correlated with prolonged OS, while neutralizing the CCR9/CCL25 axis in mice stimulated tumor progression. The expansion of CLA-expressing effector memory CD8+ T cells in response to a single administration of CTLA4 blockade predicted disease control at 3 months in 47 patients with MMel. Thus, specific CCR/CXCR expression patterns on circulating T lymphocytes may guide potential diagnostic and therapeutic approaches.
- 1 February 2016
- Published by Elsevier in European Journal of Cancer
- Vol. 54, 112-119
Rationale for anti-CD137 cancer immunotherapy
- 1 February 2016
- Published by Elsevier in European Journal of Cancer
- Vol. 54, 112-119
Rationale for anti-CD137 cancer immunotherapy
- Open Access
- 2 December 2015
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 6, 601
Natural Killer Cell Immunomodulation: Targeting Activating, Inhibitory, and Co-stimulatory Receptor Signaling for Cancer Immunotherapy
There is compelling clinical and experimental evidence to suggest natural killer (NK) cells play a critical role in the recognition and eradication of tumors. Efforts at using NK cells as antitumor agents began over two decades ago, but recent advances in elucidating NK cell biology have accelerated the development of NK cell-targeting therapeutics. NK cell activation and the triggering of effector functions is governed by a complex set of activating and inhibitory receptors. In the early phases of cancer immune surveillance, NK cells directly identify and lyse cancer cells. Nascent transformed cells elicit NK cell activation and are eliminated. However, as tumors progress, cancerous cells develop immunosuppressive mechanisms that circumvent NK cell-mediated killing, allowing for tumor escape and proliferation. Therapeutic intervention aims to reverse tumor-induced NK cell suppression and sustain NK cells’ tumorlytic capacities. Here, we review tumor-NK cell interactions, discuss the mechanisms by which NK cells generate an antitumor immune response, and discuss NK cell-based therapeutic strategies targeting activating, inhibitory, and costimulatory receptors.
- 2 December 2015
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 6, 601
Open AccessNatural Killer Cell Immunomodulation: Targeting Activating, Inhibitory, and Co-stimulatory Receptor Signaling for Cancer Immunotherapy
There is compelling clinical and experimental evidence to suggest natural killer (NK) cells play a critical role in the recognition and eradication of tumors. Efforts at using NK cells as antitumor agents began over two decades ago, but recent advances in elucidating NK cell biology have accelerated the development of NK cell-targeting therapeutics. NK cell activation and the triggering of effector functions is governed by a complex set of activating and inhibitory receptors. In the early phases of cancer immune surveillance, NK cells directly identify and lyse cancer cells. Nascent transformed cells elicit NK cell activation and are eliminated. However, as tumors progress, cancerous cells develop immunosuppressive mechanisms that circumvent NK cell-mediated killing, allowing for tumor escape and proliferation. Therapeutic intervention aims to reverse tumor-induced NK cell suppression and sustain NK cells’ tumorlytic capacities. Here, we review tumor-NK cell interactions, discuss the mechanisms by which NK cells generate an antitumor immune response, and discuss NK cell-based therapeutic strategies targeting activating, inhibitory, and costimulatory receptors.
- Open Access
- 17 November 2015
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 3 (1) , 48
A quantitative analysis of therapeutic cancer vaccines in phase 2 or phase 3 trial
Despite the progress that has been made in other forms of cancer therapy, Provenge® (Sipuleucel-T) is the only FDA-approved vaccine for the treatment of cancer. To understand the current landscape of therapeutic oncology vaccines we performed a quantitative analysis of phase 2 and phase 3 therapeutic cancer vaccine trials. We highlight shifts in trends for the vaccine platforms examined, common adjuvant use, target indications, antibody or treatment combinations between past and recent trials as well as discuss the relationship between these trends and ratio between the number of phase 3: phase 2 for different vaccine platforms. Despite the poor success rate in vaccine approvals, registration of phase 3 trials between 2010 and 2014 were stable indicating continued investment and efforts towards development of immunotherapeutic vaccines.
- 17 November 2015
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 3 (1) , 48
Open AccessA quantitative analysis of therapeutic cancer vaccines in phase 2 or phase 3 trial
Despite the progress that has been made in other forms of cancer therapy, Provenge® (Sipuleucel-T) is the only FDA-approved vaccine for the treatment of cancer. To understand the current landscape of therapeutic oncology vaccines we performed a quantitative analysis of phase 2 and phase 3 therapeutic cancer vaccine trials. We highlight shifts in trends for the vaccine platforms examined, common adjuvant use, target indications, antibody or treatment combinations between past and recent trials as well as discuss the relationship between these trends and ratio between the number of phase 3: phase 2 for different vaccine platforms. Despite the poor success rate in vaccine approvals, registration of phase 3 trials between 2010 and 2014 were stable indicating continued investment and efforts towards development of immunotherapeutic vaccines.
- 3 October 2015
- Published by Springer Nature in Current Hematologic Malignancy Reports
- Vol. 10 (4) , 438-447
Targets, Toxins, and T Cells—a Review of New Monoclonal Antibodies in the Treatment of Peripheral T Cell Lymphomas
The peripheral T cell lymphomas (PTCLs) are a heterogeneous group of neoplasms for which standardized treatment approaches remain elusive. A number of new therapeutic agents have become available, of which monoclonal antibodies (MAbs) represent a powerful tool for targeted treatment of PTCLs. Therapeutic MAbs vary in their structure, targets, and mechanisms of action. Common mechanisms of action include antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity, direct apoptosis, blocking of receptors or signaling pathways, delivery of cytotoxic agents to tumor cells, and binding to and blocking biologically active molecules. This review will focus on recent published evidence for the various MAbs used in the treatment of PTCLs. The results overall have been very promising, and the future will see more trials with these antibodies alone and in various therapy combinations, as well as newer ones with novel modifications, conjugates, and targets.
- 3 October 2015
- Published by Springer Nature in Current Hematologic Malignancy Reports
- Vol. 10 (4) , 438-447
Targets, Toxins, and T Cells—a Review of New Monoclonal Antibodies in the Treatment of Peripheral T Cell Lymphomas
The peripheral T cell lymphomas (PTCLs) are a heterogeneous group of neoplasms for which standardized treatment approaches remain elusive. A number of new therapeutic agents have become available, of which monoclonal antibodies (MAbs) represent a powerful tool for targeted treatment of PTCLs. Therapeutic MAbs vary in their structure, targets, and mechanisms of action. Common mechanisms of action include antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity, direct apoptosis, blocking of receptors or signaling pathways, delivery of cytotoxic agents to tumor cells, and binding to and blocking biologically active molecules. This review will focus on recent published evidence for the various MAbs used in the treatment of PTCLs. The results overall have been very promising, and the future will see more trials with these antibodies alone and in various therapy combinations, as well as newer ones with novel modifications, conjugates, and targets.